Cost-Effectiveness Of Idelalisib In Combination With Rituximab For The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) In Portugal
AuthID
P-00G-RMF
P-00G-RMF
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service